top of page
  • Not yet recruiting

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

Modakafusp alfa (Formerly TAK-573)

Modakafusp Alfa

NCT05556616: Phase 1: A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma


The main aims of this study is to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found. Participants will be given modakafusp alfa through a vein.

Sponsor:

Takeda

 

ClinicalTrials.gov Identifier: NCT05556616

Official Title: A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa as Part of Combination Therapy in Adult Patients With Multiple Myeloma

First Posted : September 27, 2022

Click here to see details on ClinicalTrials.gov

 

Drug: Modakafusp alfa

Drug: Lenalidomide